Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Avidity Biosciences Inc. (RNA) Insider Trading Activity
Healthcare • Biotechnology • 253 employees
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Total Value
-$9,453,831.77
Total Shares
165,794
Average Trade Value
-$201,145.36
Most Active Insider
Mac Lean Michael F
Total Activity: $5,968,220
Largest Single Transaction
$2,954,954
by Mac Lean Michael F on Nov 6, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Program Officer
Officer
|
Mar 3, 2025 | 5,875 | $86,363 | 56,429 (+10.4%) | Exercise/Conversion | |
|
Chief Program Officer
Officer
|
Mar 3, 2025 | 5,875 | $172,807 | 50,554 (-11.6%) | Sale | |
|
Chief Program Officer
Officer
|
Feb 3, 2025 | 5,875 | $188,918 | 50,554 (-11.6%) | Sale | |
|
Chief Program Officer
Officer
|
Feb 3, 2025 | 5,875 | $97,819 | 56,429 (+10.4%) | Exercise/Conversion | |
|
Chief Program Officer
Officer
|
Jan 22, 2025 | 5,629 | $169,776 | 50,554 (-11.1%) | Sale | |
|
Chief Scientific Officer
Officer
|
Jan 21, 2025 | 1,812 | $51,809 | 91,975 (-2.0%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 21, 2025 | 2,032 | $58,096 | 82,428 (-2.5%) | Sale | |
|
Director
|
Jan 21, 2025 | 1,872 | $53,537 | 12,958 (-14.4%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 21, 2025 | 1,915 | $54,760 | 84,460 (-2.3%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Jan 21, 2025 | 1,221 | $34,917 | 104,908 (-1.2%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Jan 21, 2025 | 1,738 | $49,695 | 106,129 (-1.6%) | Sale | |
|
Chief Program Officer
Officer
|
Jan 21, 2025 | 1,817 | $51,953 | 56,183 (-3.2%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 21, 2025 | 1,665 | $47,608 | 104,655 (-1.6%) | Sale | |
|
Chief Program Officer
Officer
|
Jan 21, 2025 | 1,295 | $37,024 | 58,670 (-2.2%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 21, 2025 | 1,622 | $46,378 | 106,320 (-1.5%) | Sale | |
|
Chief Program Officer
Officer
|
Jan 21, 2025 | 670 | $19,159 | 58,000 (-1.2%) | Sale | |
|
President and CEO
Director, Officer
|
Jan 21, 2025 | 4,738 | $135,475 | 343,070 (-1.4%) | Sale | |
|
President and CEO
Director, Officer
|
Jan 21, 2025 | 5,659 | $161,817 | 337,411 (-1.7%) | Sale | |
|
Chief Scientific Officer
Officer
|
Jan 21, 2025 | 3,860 | $110,383 | 93,787 (-4.1%) | Sale | |
|
Chief Legal Officer
Officer
|
Jan 6, 2025 | 25,000 | $0 | 50,000 (+50.0%) | Grant | |
|
Chief Human Resources Officer
Officer
|
Jan 6, 2025 | 25,000 | $0 | 107,867 (+23.2%) | Grant | |
|
Chief Financial Officer
Officer
|
Jan 6, 2025 | 25,000 | $0 | 107,942 (+23.2%) | Grant | |
|
Chief Technical Officer
Officer
|
Jan 6, 2025 | 40,000 | $0 | 40,000 (+100.0%) | Grant | |
|
Chief Commercial Officer
Officer
|
Jan 6, 2025 | 25,000 | $0 | 61,120 (+40.9%) | Grant | |
|
Chief Program Officer
Officer
|
Jan 6, 2025 | 25,000 | $0 | 59,965 (+41.7%) | Grant | |
|
President and CEO
Director, Officer
|
Jan 6, 2025 | 82,500 | $0 | 347,808 (+23.7%) | Grant | |
|
Chief Medical Officer
Officer
|
Jan 6, 2025 | 25,000 | $0 | 86,375 (+28.9%) | Grant | |
|
Chief Scientific Officer
Officer
|
Jan 6, 2025 | 25,000 | $0 | 97,647 (+25.6%) | Grant | |
|
President and CEO
Director, Officer
|
Dec 18, 2024 | 31,855 | $1,040,384 | 265,308 (-12.0%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Dec 18, 2024 | 11,151 | $364,192 | 82,867 (-13.5%) | Sale | |
|
Csto
Officer
|
Dec 18, 2024 | 12,742 | $416,154 | 72,647 (-17.5%) | Sale | |
|
Chief Financial Officer
Officer
|
Dec 18, 2024 | 11,151 | $364,192 | 82,942 (-13.4%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Dec 16, 2024 | 25,000 | $355,500 | 119,018 (+21.0%) | Exercise/Conversion | |
|
Chief Human Resources Officer
Officer
|
Dec 16, 2024 | 25,000 | $831,605 | 94,018 (-26.6%) | Sale | |
|
Csto
Officer
|
Dec 11, 2024 | 24,000 | $539,280 | 109,389 (+21.9%) | Exercise/Conversion | |
|
Csto
Officer
|
Dec 11, 2024 | 24,000 | $858,401 | 85,389 (-28.1%) | Sale | |
|
Director
|
Nov 19, 2024 | 3,323 | $4,121 | 18,153 (+18.3%) | Exercise/Conversion | |
|
Director
|
Nov 19, 2024 | 3,323 | $139,973 | 14,830 (-22.4%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Nov 18, 2024 | 25,000 | $1,028,520 | 94,018 (-26.6%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Nov 18, 2024 | 25,000 | $355,500 | 119,018 (+21.0%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Nov 6, 2024 | 13,875 | $629,008 | 94,093 (-14.7%) | Sale | |
|
Chief Financial Officer
Officer
|
Nov 6, 2024 | 65,182 | $574,905 | 159,275 (+40.9%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Nov 6, 2024 | 27,262 | $1,260,017 | 94,093 (-29.0%) | Sale | |
|
Chief Financial Officer
Officer
|
Nov 6, 2024 | 13,875 | $91,159 | 107,968 (+12.9%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Nov 6, 2024 | 65,182 | $2,954,954 | 94,093 (-69.3%) | Sale | |
|
Director
|
Oct 21, 2024 | 5,000 | $233,168 | 14,830 (-33.7%) | Sale | |
|
Director
|
Oct 21, 2024 | 5,000 | $6,200 | 19,830 (+25.2%) | Exercise/Conversion |